INVESTOR ALERT: Investigation of EDAP TMS S.A. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of EDAP TMS S.A. (“EDAP” or the “Company”) (NASDAQ:EDAP) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning EDAP’s business and financial prospects.

Please contact Casey Sadler, Esquire, at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

EDAP, through its subsidiaries, develops, produces and markets minimally invasive medical devices for the treatment of urological diseases. The investigation relates to the July 28, 2014, disclosure that Food and Drug Administration (“FDA”) staff questioned EDAP’s safety and effectiveness data because the Company compared patients in two different studies to gather evidence, rather than a head-to-head trial. The investigation also relates to the FDA’s July 30, 2014, announcement that the panel convened to review EDAP’s submission unanimously found that EDAP had failed to demonstrate the efficacy of its product or that it had demonstrated that the benefits of the device outweighed its risk. On this news, shares of EDAP declined more than 40 percent in after-hours trading.

If you purchased shares of EDAP, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.